Showing posts with label Suzlon. Show all posts
Showing posts with label Suzlon. Show all posts

Tuesday, June 21, 2011

Suzlon Buy on declines

/photo.cms?msid=8900924
Suzlon

After reporting losses for several quarters, Suzlon finally managed to turn green in Q4 of 2010-11 and reported a consolidated net profit of Rs 431.59 crore.

Analysts are bullish about its future prospects because Suzlon was able to weather the competition from MNCs like Siemens , Gamesha and GE and able to increase order backlog by 107% to Rs 12,800 crore.

They also state that around 80% of Suzlon India's sales volume in 2010-11 was booked from orders that were won in 2010-11 itself and therefore, Suzlon should be able to maintain margins in 2011-12 as well.

However, they advise caution since the stock is quoting at around 60% premium to its global peers. Consider investing in this counter only when it corrects.

Source ET

Our Recommendation :
Buy on declines around 45 levels for a immediate target of 60 exit and buy once again. It is a traders delight and will give decent returns on a 3 months basis.

Bought to you by

Ingenious Investor
Equity Research Division

Ravina Consulting
Pattamal Plaza
3rd Cross Kamanahalli
BANGALORE 560084

For Free Stock Advise + Ideas
sowmya@ravinaconsulting.com
Talk / SMS 08105737966

Read - www.ingeniousinvestor.blogspot.com
Follow us - www.twitter.com/smartinvestor

Tuesday, April 14, 2009

Technicals - Icici, Punj Lloyd, Suzlon, Unitech & LIC Housing


ICICI Bank

Current price: Rs 398
Target price: Rs 365

The stock is ripe for some profit-booking. It's hitting resistance above Rs 400. On the downside, there is support between Rs 360-Rs 370 and that is likely to be tested on intra-day basis at least. Keep a stop at Rs 405 and go short. Book profits below Rs 365. Be prepared for 10 per cent intra-day swings. 

Punj Lloyd

Current price: Rs 114
Target price: Rs 125

The stock has made what seems like a valid breakout from a base at Rs 105. It has a potential target of Rs 125. Keep a stop at Rs 110 and go long. Start booking profits above Rs 122. If the stock dips below Rs 106, the next reliable support is at Rs 97. So a short would be possible. 

Suzlon Energy

Current price: Rs 57.5
Target price: Rs 63

The stock has made a breakout past resistance at Rs 54 on a volume expansion. It has a potential target of Rs 63 and perhaps Rs 65. Keep a stop at Rs 55 and go long. There is massive resistance at Rs 67- Rs 68 so the stock is very unlikely to cross the level. 

LIC Housing

Current price: Rs 282
Target price: Rs 300

The stock has broken out past resistance at Rs 250 on high volumes. It could achieve a target of about 300. Keep a stop at Rs 276 and go long. Be prepared for major bursts of volatility in what is usually a very stable stock. Book some profits above the Rs 290-mark. 

Unitech

Current price: Rs 42
Target price: Rs 48

The stock has moved up on strong volume expansion. It has a potential upside till the Rs 48 level and if there is a burst of profit-booking, it could collapse back till the Rs 37-Rs 38 level. Keep a stop at Rs 40.5 and go long. Start booking profits above Rs 46.

Source BS 13-04-09

Monday, April 6, 2009

Brokerage Recs - Suzlon, Piramal Healthcare, Jindal Saw, reliance ind, cadila


Analysts' corner S I Team / Mumbai April 6, 2009, 0:44 IST SUZLON ENERGY Reco price: Rs 47 Current market price: Rs 50.75 Target price: Rs 60 Downside:18.2% Brokerage: India Infoline Suzlon has won a 43MW repeat order from Duke Energy, USA. Over the past two months, it has received orders aggregating 387MW from leading international players, increasing its order book to 2,303MW; 1437MW is executable over FY10. Such constant order inflows should help allay concerns on quality issues, and the company’s ability to get new orders. Suzlon has underperformed the broader markets by 27 per cent in the last three months, primarily because of concerns on quality issues and high leverage on its books. While the recent move in the stock price can be attributed to a pick-up in order intake, challenges in fund-raising remains a key concern. The company intends to meet this funding gap through equity dilution at Suzlon/Hansen level and reduction in the working capital. Also, it has initiated a programme to restructure debt covenants on its FCCBs. While the stock is currently trading at a modest valuation, it reflects the funding issues Any further re-rating would depend on the company’s ability to mobilise funds. Possible postponement of payment to Martifer would alleviate pressure on Suzlon to mobilise funds immediately and act as a catalyst for the stock. PIRAMAL HEALTHCARE Reco price: Rs 194 Current market price: Rs 201.80 Target price: Rs 261 Downside: 29.3% Brokerage: Emkay Research Piramal Healthcare’s decision to discontinue its Huddersfield facility will mean a one-time hit of Sterling pound 10.1 million. The company will be shifting these contracts to Digwal (India) and Morpeth (UK) facilities. On the operating level, the company expects an expansion of 6-8 percentage points (or 600-800 basis points) in margins mainly driven by the close down of Huddersfield facility, increase in early phase pipeline, cost improvement and clinical packaging offerings at Morpeth, and strong commercial projects pipeline at Digwal. However, because of shifting of contracts and temporary slowdown in CMG space, the company has indicated that its revenues from the pharma solution business will be lower by five per cent in FY10 as compared to FY09. While the brokerage believes that restructuring of the pharma solution business is a long term positive, it has downgraded revenue estimates by 11 per cent each for FY10 and FY11 and earnings estimates by 9 per cent and 8 per cent, respectively. The stock is traing at 8.6x estimated FY10 EPS of Rs 22.6. JINDAL SAW Reco price: Rs 175 Current market price: Rs 182.35 Target price: Rs 476 Downside:161 Brokerage: Sharekhan Jindal Saw Ltd’s (JSL) Q4CY08 numbers are ahead of expectations on the back of a strong top line. With the hive-off of the US division, the results are not strictly comparable. The revenues declined by 3.9 per cent year-on-year (yoy), but marked a growth of 4.2 per cent quarter-on-quarter (qoq) to Rs 1,548 crore. As expected, operating margins were lower at 12.5 per cent even on sequential comparison (13.4 per cent in Q3) due to higher execution cost of Cairn Energy India’s order, which was taken at lower margins. Higher interest and taxes led to a decline of 21.3 per cent yoy and 13.4 per cent qoq in its profits to Rs 86.7 crore. JSL’s order book has fallen from about $1 billion to $840 million. It has participated in various bids and is in the final stages of closing a significant order for HSAW pipes, which is likely to boost its order book going forward. However, in the scenario of slackening orders, players in the space are likely to cut on their margins to boost order books. Thus, EPS estimates for JSL are reduced by 11.2 per cent for CY09 to Rs 79.3. The stock is trading at attractive valuations of 2.2x its CY09E earnings and at an EV/EBIDTA of 1.5x. Historically, it has reached the trough valuations seen in 2002-2003. RELIANCE INDUSTRIES Reco price: Rs 1,523 Current market price: Rs 1,662.50 Target price: Rs 1,710 Downside: 2.9% Brokerage: Edelweiss Securities Crude oil and natural gas prices are denominated in dollar. The $/Re is estimated to be weaker by 1.6 per cent to 45.8 in FY09 and by 11.5 per cent each to 49.0 and 47.5 in FY10 and FY11, respectively. Thus, Reliance Industries’ (RIL) earnings are expected to improve on account of higher crude and natural gas realisations and gross refining margins (GRMs) in rupee terms. Further, KG-D6 gas price assumption has also been revised upwards from $ 3.75/mmbtu to $ 4.2/mmbtu. In line with weaker $/Re outlook and neutral impact of change in KG-D6 basin gas pricing assumption, RIL’s post-merger EPS estimates for FY10 and FY11 have been revised by 12.3 per cent and 16.9 per cent to Rs 135.9 and Rs 173.0, respectively. Likewise, the sum-of-the-parts estimate has been increased to Rs 1,710 per share (Rs 1,525 per share earlier). The long-term view on the stock remains positive and, RIL’s portfolio of blocks could give significant upsides. However, any rupee appreciation and reduction in duty differential may affect GRMs and are key risks, going ahead. At Rs 1,523, RIL trades at FY09E and FY10E P/E of 16.3x and 11.2x, respectively, and at FY09E and FY10E EV/EBITDA of 11.8x and 7.7x, respectively. CADILA HEALTHCARE Reco price: Rs 271 Current market price: Rs 274 Target price: Rs 350 Downside: 27.7% Brokerage: Angel Broking The recent R&D collaboration deal of Cadila with Eli Lilly involves discovery and development of potential molecules primarily in cardiovascular research. Cadila will initiate drug discovery, lead identification, conduct pre-clinical studies and clinical trials up to Phase IIa (Human Proof-of-Concept). Cadila will receive milestone payments during the development process up to a maximum of $300 million and royalties on sale of products ultimately launched. However, Cadila will incur the upfront costs and will be reimbursed once the specific milestones are achieved. The deal is positive as it corroborates Cadila’s capabilities, although material cash flow would come over long term, and may further unlock value for its R&D business. While overdependence on Nycomed has been a major concern for Cadila, new client additions in the segment would aid de-risking. Further, the Hospira joint venture is expected to commercialise in April 2009 and start contributing to the company’s bottom line from FY10. Excluding any upsides from the JVs and factoring in a decline in the profitability of Nycomed, the brokerage expects Cadila to post a CAGR of 24 per cent in net profit over FY 2008-10E. The stock is trading at 11.3x FY2009E and 9.3x FY2010E earnings. Current market price as on April 2, 2009 source : business-standard

Saturday, March 28, 2009

Suzlon Energy - Buy on declines

Vidya Bala

Investors with an over three-year perspective can consider accumulating the stock of Suzlon Energy. While there is no denying that Suzlon is the least decoupled from the global slowdown and is also plagued by internal challenges such as the defective blade issue and funding for acquisition, its current valuations have clearly factored in more negatives than perhaps exist now.

The huge potential for renewable energy in the long term and the company’s sound business strategy to tap global opportunities strengthens the case for buying the stock at rock-bottom valuations. At the current market price of Rs 35, the stock trades at four times its expected earnings for FY-10. Investors may, however, have to be prepared for a sedate performance in FY-09. The high volatility in the stock warrants buying it in small quantities on declines.

Why the poor results

A good part of Suzlon’s recent stock decline occurred after the company’s December quarter results, when it posted losses mainly on account of exceptional items. On a consolidated basis, the company made losses of Rs 34.9 crore mainly on account of notional forex losses and a provision for blade retrofit also amounted to Rs 449 crore.

The defective blade issue: While the first is an accounting treatment to comply with accounting standards, the other expense amounting to Rs 233 crore was incurred as part of its retrofit programme for a particular version (S88 V2) of blades that were found to be defective. The provision made was on account of higher cost of replacement as a result of longer period to find the root cause before rectification.

The company has stated that most of the provisioning is done with and nothing significant may have to be provided for in the coming months. Further, as the company has already moved ahead to the next version (V3) and installed the same without any reported cases of defect over the past one year, we believe this provisioning is unlikely to extend much in to the future.

Acquisition-related debt: High interest costs, mostly on account of acquisition-related debt, have also resulted in a strain on profits. However, the company is likely to retire about Rs 250 crore of the acquisition debt in 2009 and one more tranche by June and September. The company intends to repay these amounts partly through the recent stake sale in its subsidiary, Hansen Transmission, which resulted in cash inflows of Rs 550 crore. With this, we expect the debt-equity ratio to reduce to at least 0.8:1 from 1:1 at present.

Leaving alone these two factors, the company’s operations have remained fairly healthy. The Suzlon group alone witnessed a good 53 per cent increase in operating profits for the December 2008 quarter compared to a year ago numbers.

Operating profit margins too expanded by a marginal 30 basis points to 12.8 per cent for the same group (the fully consolidated numbers are not comparable as a result of REpower’s inclusion in the December 08 quarter).

Working capital: Suzlon has accumulated huge inventories this quarter, further dragging its working-capital cycle. The build-up can be partly explained by the US slowdown and perhaps the quality concern overhang resulting from the blade defect issue.

Of its current order book of close to 2,200 MW, at least 800 MW is executable in the last quarter of FY09. Such an execution is likely to ease the working capital strain by way of inventory liquidation. The company may also resort to lower advance purchases of components given the global slowdown and reduced demand. Such a move too can improve working capital.

Acquisition concern

Another near-term concern that has been dragging the stock of Suzlon is the means of funding to pay €205 million (Rs 1,332 crore), for Martifer’s stake in REpower over April and May 2009. For now, the company has a three-pronged strategy for the same. One, it hopes to generate part of the amount through funds released from reduced working-capital requirements. Two, a further stake sale in Hansen (but retaining control) is an option. Three, external borrowings may be resorted to.

Plan 1 appears plausible given that reduced inventory and lower commodity prices could well be a reality in the fourth quarter. A stake sale in Hansen is also not impossible given that it can sell up to 10 per cent and yet maintain a 51 per cent stake. A similar stake sale recently brought in about £73 million (Rs 530 crore). Such a strategy would also not materially affect the earnings picture for Suzlon shareholders. The third strategy though may once again bring the debt to less comfortable levels.

That the company has strategies lined up to address the funding concern provides comfort to its ability to tackle adversity. More importantly, the persistence shown by the company in this acquisition, its success in negotiating for a longer payment period with Martifer and its willingness to carry the burden of low-profit margin foreign associates also suggests its seriousness in gaining a foothold in the robust EU wind market.

These moves, though beset with short-term risks, if overcome, could well generate high returns on integration. These are also clear indicators for an investor that the company is pursuing an aggressive growth model and is a high-risk high-return proposition.

Business opportunities

Suzlon has seen a revival in order flows with the recent projects bagged in Australia and China. The company expects to receive at least 1,000 MW of the 2,000 MW of projects that are currently in its pipeline. While markets outside of the US may hold better opportunities in 2009, the US market, once there appears a revival, could yet hold huge potential given the extension of the production tax credits unto 2012 passed by the US Senate. Other incentives include a $7-billion renewable energy loan guarantee programme, an additional year of bonus depreciation and incentives for small wind investments.

The potential in the Indian market too appears enhanced what with a few states offering higher tariffs for captive investment in wind energy. Further, a number of public sector companies such as ONGC, HPCL are starting to invest in renewable energy to meet the Central target.

Weighing the fortunes of the renewable energy based on price of crude oil alone, as the market appears to be doing now, therefore, appears short-sighted. Regulations, incentives and the planned wind energy programmes for various economies in the context of the slowdown, should instead be the deciding factors for assessing the prospects of the wind energy market.

businessline 08-03-09

Investment Strategy Now :

Our View :


The prices have run up in the last week too fast and with this speed it can
touch Rs.46. One should not invest at this high price but should start buying
around Rs.35 levels for a decent gain over a 12 months period.